Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of topical omiganan for usual-type vulvar intraepithelial neoplasia
NL-OMON42712Phase 2Active, not recruiting
- Sponsor
- Biofrontera
- Start
- Nov 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vulvar intraepithelial neoplasia (VIN) comparing Omiganan 2.5% gel with Placebo gel (2 arms). Primary endpoints: Pharmacodynamic effect of topical omiganan on uVIN lesions and Treatment effect versus placebo in uVIN patients. Started Nov 2015; status: active, not recruiting.
02
Drugs
omiganan
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NL-OMON42712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42712.